Predictmedix (PMED) AI Stock Analysis

• Market Cap: $6.74M
• Dividend Yield: N/A
• Average Volume (3M): 284.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: 24.18%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 192,534,550
• 10 Day Avg. Volume: 239,901
• 30 Day Avg. Volume: 284,338
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -22.71
• Enterprise Value/Ebitda: -2.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

The overall stock score for Predictmedix is driven by its significant financial challenges, including negative revenue and profitability, and a weak balance sheet. While technical indicators show short-term positive momentum, the company's poor financial health and unattractive valuation metrics weigh heavily on its score.

Predictmedix Business Overview & Revenue Model

Company Description

Predictmedix (PMED) is a technology company that operates in the healthcare sector, specializing in artificial intelligence (AI) driven solutions. The company focuses on developing AI-powered technologies designed to enhance workplace health and safety. Its core products include impairment detection systems and solutions for rapid health assessments, aiming to improve safety and efficiency across various industries.

How the Company Makes Money

Predictmedix generates revenue primarily through the sale and licensing of its AI-driven technologies. The company offers its products to businesses across sectors such as healthcare, manufacturing, and public safety. Key revenue streams include direct sales of hardware and software solutions, subscription-based services for ongoing access to their AI platforms, and partnerships with third-party vendors and service providers who integrate Predictmedix's technologies into their own offerings. Additionally, the company may engage in research and development collaborations that provide additional funding and resources.

Predictmedix Financial Statement Overview

Summary

Predictmedix exhibits significant financial challenges across all metrics, with declining revenue and profitability, weak balance sheet health due to negative equity, and poor cash flow dynamics. The company must address operational inefficiencies and improve its revenue generation to enhance financial stability.

Income Statement

The company has struggled with generating revenue and maintaining profitability. Persistent negative net income and declining total revenue, particularly with zero revenue in the latest fiscal year, reflect significant challenges. The gross and net profit margins are negative, indicating inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a weak financial position with negative stockholders' equity, indicating liabilities exceed assets. The equity ratio is negative, further highlighting financial distress. However, the absence of total debt provides a slight buffer against solvency risk.

Cash Flow

The company has consistently negative operating and free cash flows, with significant cash burn. While financing cash flow is positive, indicating reliance on external funding, this is unsustainable without positive operating cash flow. The free cash flow to net income ratio is unfavorable, showing cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	35.02K	134.82K	0.00
Gross Profit	-164.60K	-155.31K	-167.63K	26.62K	84.82K	-3.51K
EBITDA	-1.62M	-788.14K	-1.82M	-1.91M	-1.80M	-1.93M
Net Income	-1.79M	-1.18M	-1.99M	-2.07M	-1.88M	-1.93M
Balance Sheet
Total Assets	457.04K	131.95K	481.33K	717.74K	1.24M	1.00M
Cash, Cash Equivalents and Short-Term Investments	28.79K	0.00	36.87K	79.25K	211.30K	480.05K
Total Debt	0.00	0.00	0.00	37.87K	0.00	15.19K
Total Liabilities	874.70K	1.45M	625.14K	871.12K	349.67K	135.35K
Stockholders Equity	-417.66K	-1.32M	-143.82K	-153.39K	886.99K	868.29K
Cash Flow
Free Cash Flow	-1.01M	-36.87K	-1.64M	-678.85K	-1.95M	-1.27M
Operating Cash Flow	-1.01M	-36.87K	-1.64M	-534.17K	-1.53M	-1.08M
Investing Cash Flow	0.00	0.00	0.00	-144.68K	-418.12K	-195.01K
Financing Cash Flow	1.01M	0.00	1.60M	546.80K	1.68M	261.12K

Predictmedix Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PMED, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:PMED.

Predictmedix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PINK	45 Neutral	C$28.51M	―	-233.44%	―	219.12%	-15.92%
THRM	45 Neutral	$4.26M	―	-224.63%	―	57.50%	16.20%
VPT	44 Neutral	C$17.61M	―	207.08%	―	88.47%	11.88%
TLT	44 Neutral	C$50.13M	―	-291.69%	―	16.00%	9.79%
ASTI	37 Underperform	$275.99K	―	16.76%	―	-52.36%	70.49%
PMED	35 Underperform	$6.74M	―	1386.11%	―	―	24.18%